For preventing bone metastases in women with early breast cancer, the current body of evidence does not support the use of osteoclast-targeting agents, ie, bisphosphonates, according to Julie Gralow, MD, director of Breast Medical Oncology at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Read More ›

According to a study from the US Oncology Network, breast cancer patients treated with adjuvant chemotherapy have no increased risk for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), at least within the first 3 years of treatment. The study was presented at the American Society of Clinical Oncology 2012 Breast Cancer Symposium by Neelima Denduluri, MD, of Virginia Cancer Specialists.¹ Read More ›

Updated results from the pivotal phase 3 BOLERO-2 trial uphold, and even add to, the previous benefits reported for the addition of everolimus to exemestane in advanced breast cancer, including a positive effect on bone markers. Read More ›

In women with metastatic breast can­cer, less frequent dosing of zoledronic acid (ZA) may be as protective as the standard monthly infusion, according to 2 studies presented at the 2012 Annual Meeting of the American So­ciety of Clinical Oncology (ASCO). Read More ›

According to an analysis of the Eastern Cooperative Oncology Group trial ECOG-E1199 by Schneider and colleagues, the development of grade 2 to 4 peripheral neuropathy in patients with operable breast cancer who received taxanes does not appear to affect clinical outcome. Read More ›

Adverse events (AEs) related to chemotherapy for metastatic breast cancer (MBC) create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said Sara A. Hurvitz, MD, of the University of California Los Angeles, who presented an economic analysis at the 2012 Annual Meeting of the American Society of Clinical Oncology. Read More ›

Early breast cancer patients who gain weight after treatment are at increased risk for breast cancer recurrence, according to an Italian study presented at the European Society for Medical Oncology 2012 Congress, held in Vienna, Austria. Read More ›

Three commonly used radiological tests rarely detect metastases in newly diagnosed breast cancer patients and should not be routinely performed, according to a comprehensive literature review presented at the American Society of Clinical On­cology (ASCO) 2012 Breast Cancer Symposium, held in San Francisco, California. Read More ›

Expanded utility of the 21-gene recurrence score (RS) (Onco­type DX) was shown in a retrospective analysis reported at the American Society of Clinical Oncology 2012 Breast Cancer Symposium by investigators from the National Surgical Adjuvant Breast and Bowel Project (NSABP). Read More ›

The biggest newsmaker at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) was a compound whose name and actions sound practically missile-like: T-DM1. Because of its highly targeted and potent effect that spares surrounding healthy tissue, T-DM1 not only has potent antitumor effects but is also very well tolerated.

Read More ›